王莹,赵潇霄,颜红兵

• 1:国家心血管病中心北京协和医学院中国医学科学院阜外医院冠心病中心
• 2:国家心血管病中心中国医学科学院阜外医院深圳医院冠心病中心

摘要(Abstract)：

<正>尽管采用了标准二级预防策略,每年仍有5%～10%心血管疾病患者再次发生心血管事件[1-3]。在美国心脏病学会2020年会上发表的COMPASS(Cardiovascular Outcomes for People Using Anticoagulation Strategies)糖尿病亚组分析显示,应用低剂量Xa因子抑制药利伐沙班联合阿司匹林(双路径抑制),可以降低稳定动脉粥样硬化(合并有或无糖尿病)患者主要不良心血管事件(major adverse cardiac event,MACE)发生率[4]。

关键词(KeyWords)： 糖尿病;稳定动脉粥样硬化

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 王莹,赵潇霄,颜红兵

参考文献(References)：

• [1]Ohman EM,Bhatt DL,Steg PG,et al.The reduction of atherothrombosis for continued health(REACH)registry:an international,prospective,observational investigation in subjects at risk for atherothrombotic events-study design.Am Heart J,2006,151(4):786.e1-e10.
• [2]Bhatt DL,Eagle KA,Ohman EM,et al.Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis.JAMA,2010,304(12):1350-1357.
• [3]Miao B,Hernandez AV,Alberts MJ,et al.Incidence and predictors of major adverse cardiovascular events in patients with established atherosclerotic disease or multiple risk factors.J Am Heart Assoc,2020,9:e014402.
• [4]Bhatt DL,Eikelboom JW,Connolly SJ,et al.The role of combination antiplatelet and anticoagulation therapy in diabetes and cardiovascular disease:insights f rom the COMPASS trial.Circulation,2020,141(23):1841-1854.
• [5]Yip C,Seneviratna A,Tan SH,et al.Patients with acute and chronic coronary syndromes have elevated long‐term thrombin generation.J Thromb Thrombolysis,2020.[Online ahead of print].
• [6]Bukowska A,Zacharias I,Weinert S,et al.Coagulation factor Xa induces an inflammatory signalling by activation of proteaseactivated receptors in human atrial tissue.Eur J Pharmacol,2013,718(1-3):114-123.
• [7]Sakamoto A,Jinnouchi H,Torii S,et al.Understanding the impact of stent and scaff old material and strut design on coronary artery thrombosis f rom the basic and clinical points of view.Bioengineering(Basel),2018,5(3):71.
• [8]Schneider JG,Isermann B,Kleber ME,et al.Inverse association of the endogenous thrombin potential(ETP)with cardiovascular death:the ludwigshafen risk and cardiovascular health(LURIC)study.Int J Cardiol,2014,176(1):139-144.
• [9]Schoenwaelder SM,Yuan Y,Josefsson EC,et al.Two distinct pathways regulate platelet phosphatidylserine expo-sure and procoagulant function.Blood,2009,114(3):663-666.
• [10]Loeff en R,Godschalk TC,van Oerle R,et al.The hypercoagulable profile of patients with stent thrombosis.Heart,2015,101(14):1126-1132.
• [11]Borst O,Münzer P,Alnaggar N,et al.Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction.Blood Adv,2018,2(6):715-730.
• [12]Ten Cate H,Hemker HC.Thrombin generation and atherothrombosis:what does the evidence indicate?J Am Heart Assoc,2016,5:e003553.
• [13]Posma JJ,Posthuma JJ,Spronk HM.Coagulation and noncoagulation eff ects of thrombin.J Thromb Haemost,2016,14(10):1908-1916.
• [14]Gibson CM,Mega JL,Burton P,et al.Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndromethrombolysis in myocardial infarction 51(ATLAS-ACS 2 TIMI51)trial:a randomized,double-blind,placebo-controlled study to evaluate the effi cacy and safety of rivaroxaban in subjects with acute coronary syndrome.Am Heart J,2011,161(5):815-821.e6.
• [15]Mega JL,Braunwald E,Wiviott SD,et al.Rivaroxaban in patients with a recent acute coronary syndrome.N Engl J Med,2012,366(1):9-19.
• [16]Bosch J,Eikelboom JW,Connolly SJ,et al.Rationale,design and baseline characteristics of participants in the cardiovascular outcomes for people using anticoagulation strategies(COMPASS)Trial.Can JCardio,2017,33:1027-1035.
• [17]Eikelboom JW,Connolly SJ,Bosch J,et al.Rivaroxaban with or without aspirin in stable cardiovascular disease.N Engl J Med,2017,377:1319-1330.
• [18]Anand SS,Caron F,Eikelboom JW,et al.Major adverse limb events and mortality in patients with peripheral artery disease:The COMPASS Trial.J Am Coll Cardiol,2018,71:2306-2315.
• [19]Lamy A,Eikelboom J,Sheth T,et al.Rivaroxaban,aspirin,or both to prevent early coronary bypass graf t occlusion:the COMPASS-CABG study.J Am Coll Cardiol,2019,73(2):1121-1430.
• [20]Bainey KR,Welsh RC,Connolly SJ,et al.Rivaroxaban plus aspirin versus aspirin alone in patients with prior percutaneous coronary intervention(COMPASS-PCI).Circulation,2020,141(14):1141-1151.
• [21]Branch KR,Probstfi eld JL,Eikelboom JW,et al.Rivaroxaban with or without aspirin in patients with heart failure and chronic coronary or peripheral artery disease:The COMPASS Trial.Circulation,2019,140(7):529-537.
• [22]Anand SS,Eikelboom JW,Dyal L,et al.Rivaroxaban plus aspirin versus aspirin in relation to vascular risk in the COMPASS Trial.JAm Coll Cardiol,2019,73(25):3271-3280.
• [23]Bonaca MP,Bhatt DL,Cohen M,et al.Long-term use of ticagrelor in patients with prior myocardial infarction.N Engl J Med,2015,372(19):1791-1800.
• [24]Zannad F,Anker SD,Byra WM,et al.Rivaroxaban in patients with heart failure,sinus rhythm,and coronary disease.N Engl JMed,2018,379(14):1332-1342.